Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide...
55 insider purchases on record · latest filing 2025-06-17.
Insiders have also filed 37 sale transactions at PTN.